In:
Gynecologic and Obstetric Investigation, S. Karger AG, Vol. 83, No. 1 ( 2018), p. 45-51
Abstract:
〈 b 〉 〈 i 〉 Objectives: 〈 /i 〉 〈 /b 〉 To investigate whether elevated levels of CA125 (≥35 U/mL) and CA19-9 (≥37 U/mL) suggest advanced-stage disease (defined as stage II or higher) or poor prognosis in patients with borderline ovarian tumors (BOTs). 〈 b 〉 〈 i 〉 Study Design: 〈 /i 〉 〈 /b 〉 We retrospectively identified 591 patients with BOTs. Multivariate logistic regressions and Cox proportional hazard regressions were used to determine the clinicopathologic factors associated with the presence of advanced-stage disease and the prognostic factors associated with recurrence-free survival. 〈 b 〉 〈 i 〉 Results: 〈 /i 〉 〈 /b 〉 CA125 was elevated more often in serous than in mucinous tumors (50.6 vs. 35.5%; 〈 i 〉 p 〈 /i 〉 = 0.003), whereas CA19-9 was elevated more often in mucinous than serous tumors (33.6 vs. 15.3%; 〈 i 〉 p 〈 /i 〉 = 0.001). An elevated CA125 level was independently associated with the presence of advanced-stage disease in serous ( 〈 i 〉 p 〈 /i 〉 = 0.005) and in mucinous BOTs ( 〈 i 〉 p 〈 /i 〉 = 0.015). However, preoperative elevation of CA19-9, unlike CA125, was not associated with the advanced-stage disease. Elevated preoperative CA125 level ( 〈 i 〉 p 〈 /i 〉 = 0.037) was an independent prognostic factor for recurrence-free survival in patients with serous BOTs. However, neither CA125 nor CA19-9 had prognostic significance in mucinous BOTs. 〈 b 〉 〈 i 〉 Conclusions: 〈 /i 〉 〈 /b 〉 Elevated preoperative CA125, unlike CA19-9, is a diagnostic and prognostic biomarker associated with the presence of advanced-stage disease and risk of relapse in patients with serous BOTs.
Type of Medium:
Online Resource
ISSN:
0378-7346
,
1423-002X
Language:
English
Publisher:
S. Karger AG
Publication Date:
2018
detail.hit.zdb_id:
1482695-1
Permalink